Necrotizing Ulcerative Gingivitis (NUG) Treatment Market Players:
- Novartis International AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Sanofi S.A.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Abbott Laboratories
- Eli Lilly and Company
- Hindustan Antibiotics Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of necrotizing ulcerative gingivitis treatment is estimated at USD 1.51 billion.
The global necrotizing ulcerative gingivitis treatment market size was more than USD 1.36 billion in 2025 and is anticipated to grow at a CAGR of over 12.1%, reaching USD 4.26 billion revenue by 2035.
By 2035, North America is projected to secure a 32% share in the Necrotizing Ulcerative Gingivitis (NUG) Treatment Market, supported by rising oral disease prevalence, poor dietary habits, and increasing cases of diabetes.
Key players in the market include Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Eli Lilly and Company, Hindustan Antibiotics Limited.
